Péter Sandy

9.2k citations

27 papers · 3.5k indexed · 1 hit paper · h-index 17

Impact in

Hematology top 2%
- Multiple Myeloma Research and Treatments
Molecular Biology top 2%
- Protein Degradation and Inhibitors
- Ubiquitin and proteasome pathways
- Histone Deacetylase Inhibitors Research
- PI3K/AKT/mTOR signaling in cancer
- Epigenetics and DNA Methylation
- Cancer-related gene regulation

Papers in ⓘ

Hematology 5
- Multiple Myeloma Research and Treatments 4
Oncology 11
- Cancer-related Molecular Pathways 5
- CAR-T cell therapy research 3

Co-authors: Tyler Jacks (4 shared papers)Srividya Balasubramanian (2 shared papers)Louise Bergeron (2 shared papers)Andrew R. Conery (2 shared papers)Jennifer A. Mertz (2 shared papers)Barbara M. Bryant (2 shared papers)Robert J. Sims (2 shared papers)Deanna A. Mele (1 shared paper)
Journals: Cancer Research (3 papers)Journal of Biological Chemistry (3 papers)Cell (2 papers)Proceedings of the National Academy of Sciences (2 papers)Cell Death and Disease (1 paper)
Partner nations: United States Italy Germany

In The Last Decade

Péter Sandy

26 papers receiving 3.5k citations

Hit Papers

align trajectories log scale

Targeting MYC dependence in cancer by inhibiting BET bromodomains 2011 · 876 citations

Peers

Countries citing papers authored by Péter Sandy

Since Specialization

Citations

This map shows the geographic impact of Péter Sandy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Péter Sandy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Péter Sandy more than expected).

Fields of papers citing papers by Péter Sandy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Péter Sandy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Péter Sandy. The network helps show where Péter Sandy may publish in the future.

Co-authors

The 25 scholars most cited alongside Péter Sandy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Péter Sandy Line = papers co-authored together Péter Sandy links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Targeting MYC dependence in cancer by inhibiting BET bromodomains Proceedings of the National Academy of Sciences ·Jennifer A. Mertz, Andrew R. Conery, Barbara M. Bryant, Péter Sandy, Srividya Balasubramanian, Deanna A. Mele, Louise Bergeron, Robert J. Sims Hit paper breakdown →	2011	876
2	AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer DSpace@MIT (Massachusetts Institute of Technology) ·Péter Sandy, Sebastian Hoersch, Piyush B. Gupta, Tyler Jacks, Eric S. Lander	2009	430
3	Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1 The EMBO Journal ·Monica Gostissa, Arnd Hengstermann, Valentina Fogal, Péter Sandy, Sylvia E. Schwarz, Martin Scheffner, Giannino Del Sal	1999	426
4	Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells Cell ·Claudia Scholl, Stefan Fröhling, Ian F. Dunn, Anna C. Schinzel, David A. Barbie, So Young Kim, Serena J. Silver, Pablo Tamayo, Raymond Wadlow, Sridhar Ramaswamy, Konstanze Döhner, Lars Bullinger, Péter Sandy, Jesse S. Boehm, David E. Root, Tyler Jacks, William C. Hahn, D. Gary Gilliland	2009	416
5	The Ubiquitin Ligase FBXW7 Modulates Leukemia-Initiating Cell Activity by Regulating MYC Stability Cell ·Bryan H. King, Thomas Trimarchi, Linsey B. Reavie, Luyao Xu, Jasper Mullenders, Panagiotis Ntziachristos, Beatriz Aranda-Orgillés, Arianne Pérez-García, Junwei Shi, Christopher R. Vakoc, Péter Sandy, Steven S. Shen, Adolfo A. Ferrando, Iannis Aifantis	2013	252
6	Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors Proceedings of the National Academy of Sciences ·Michele Ceribelli, Priscilla N. Kelly, Arthur L. Shaffer, George W. Wright, Wenming Xiao, Yibin Yang, Lesley A. Mathews Griner, Rajarshi Guha, Paul Shinn, Jonathan M. Keller, Dongbo Liu, Paresma Patel, Marc Ferrer, Shivangi Joshi, Sujata Nerle, Péter Sandy, Emmanuel Normant, Craig J. Thomas, Louis M. Staudt	2014	144
7	Glycogen Synthase Kinase-3β Regulates NF-κB1/p105 Stability Journal of Biological Chemistry ·Francesca Demarchi, Cosetta Bertoli, Péter Sandy, Claudio Schneider	2003	138
8	Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth Chemistry & Biology ·Shivani Garapaty-Rao, Christopher G. Nasveschuk, Alexandre Gagnon, Eric Y. Chan, Péter Sandy, Jennifer Busby, Srividya Balasubramanian, Robert M. Campbell, Feng Zhao, Louise Bergeron, James E. Audia, Brian K. Albrecht, Jean-Christophe Harmange, Richard Cummings, Patrick Trojer	2013	116
9	Mammalian RNAi: a Practical Guide BioTechniques ·Péter Sandy, Andrea Ventura, Tyler Jacks	2005	95
10	Requirement of c-Jun NH ₂ -Terminal Kinase for Ras-Initiated Tumor Formation Molecular and Cellular Biology ·Cristina Cellurale, Guadalupe Sabio, Norman J. Kennedy, Madhumita Das, Marissa Barlow, Péter Sandy, Tyler Jacks, Roger J. Davis	2011	84
11	Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma eLife ·Andrew R. Conery, Richard C. Centore, Adrianne Neiss, Patricia J. Keller, Shivangi Joshi, Kerry L. Spillane, Péter Sandy, Charlie Hatton, Eneida Pardo, Laura E. Zawadzke, Archana Bommi‐Reddy, Karen E. Gascoigne, Barbara M. Bryant, Jennifer A. Mertz, Robert J. Sims	2016	84
12	The Cell Cycle-regulated Protein Human GTSE-1 Controls DNA Damage-induced Apoptosis by Affecting p53 Function Journal of Biological Chemistry ·Martín Monte, Roberta Benetti, Giacomo Buscemi, Péter Sandy, Giannino Del Sal, Claudio Schneider	2003	79
13	Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma Leukemia ·Alexandra Moros, Vanina Rodríguez, Ifigènia Saborit-Villarroya, Arnau Montraveta, Patricia Balsas, Péter Sandy, Antonio Martı́nez, Adrian Wiestner, Emmanuel Normant, Elı́as Campo, Patricia Pérez‐Galán, Dolors Colomer, Gaël Roué	2014	77
14	RNAI AS AN EXPERIMENTAL AND THERAPEUTIC TOOL TO STUDY AND REGULATE PHYSIOLOGICAL AND DISEASE PROCESSES Annual Review of Physiology ·Christopher P. Dillon, Péter Sandy, Alessio Nencioni, Stephan Kissler, Douglas A. Rubinson, Luk Van Parijs	2004	75
15	The PDZ Protein Tax-interacting Protein-1 Inhibits β-Catenin Transcriptional Activity and Growth of Colorectal Cancer Cells Journal of Biological Chemistry ·Mutsumi Kanamori, Péter Sandy, Stefania Marzinotto, Roberta Benetti, Chikatoshi Kai, Yoshihide Hayashizaki, Claudio Schneider, Harukazu Suzuki	2003	73
16	The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors Cell Death and Disease ·Chung F. Wong, Saurabh V. Laddha, Laura H. Tang, Evan Vosburgh, Arnold J. Levine, Emmanuel Normant, Péter Sandy, Chris Harris, Christina Chan, Eugenia Y. Xu	2014	50
17	p53 is involved in the p120E4F-mediated growth arrest Oncogene ·Péter Sandy, Monica Gostissa, Valentina Fogal, Loris De Cecco, Katalin Sz. Szalay, Robert J. Rooney, Claudio Schneider, Giannino Del Sal	2000	39
18	495 Trial of SNX281, a systemically delivered small molecule STING agonist, in solid tumors and lymphomas SHILAP Revista de lepidopterología ·Judy Wang, Gerald S. Falchook, Salah Nabhan, Meghana Kulkarni, Péter Sandy, Ololade Dosunmu, Humphrey Gardner, Johanna C. Bendell, Melissa L. Johnson	2021	14
19	A Transient Transgenic RNAi Strategy for Rapid Characterization of Gene Function during Embryonic Development PLoS ONE ·Bryan C. Bjork, Yuko Fujiwara, Shannon W. Davis, Haiyan Qiu, Thomas L. Saunders, Péter Sandy, Stuart H. Orkin, Sally A. Camper, David R. Beier	2010	13
20	Epi-allelic Erk1 and Erk2 knockdown series for quantitative analysis of T cell Erk regulation and IL-2 production Molecular Immunology ·Lucia Wille, Melissa L. Kemp, Péter Sandy, Christina L. Lewis, Douglas A. Lauffenburger	2007	11

About Péter Sandy

Péter Sandy is a scholar working on Hematology, Oncology, Molecular Biology, Biotechnology and Immunology, having authored 27 papers that have together received 3.5k indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (8 papers), Cancer-related Molecular Pathways (5 papers), Ubiquitin and proteasome pathways (5 papers), RNA modifications and cancer (4 papers), RNA Interference and Gene Delivery (4 papers), Multiple Myeloma Research and Treatments (4 papers), Virus-based gene therapy research (3 papers) and CAR-T cell therapy research (3 papers). The work is most often cited by research in Hematology (629 citations), Molecular Biology (3.0k citations), Oncology (994 citations), Cancer Research (429 citations) and Genetics (171 citations). Péter Sandy has collaborated with scholars based in United States, Italy and Germany. Frequent co-authors include Tyler Jacks, Srividya Balasubramanian, Louise Bergeron, Andrew R. Conery, Jennifer A. Mertz, Barbara M. Bryant, Robert J. Sims, Deanna A. Mele, Eric S. Lander and Sebastian Hoersch. Their work appears in journals such as Cancer Research, Journal of Biological Chemistry, Cell, Proceedings of the National Academy of Sciences and Cell Death and Disease.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact